



5-30-04

Ifw

EXPRESS MAIL CERTIFICATE

"Express Mail" Label No. : EV 367 776 298 US

Serial No. : 10/682,131

Applicant(s) : Jerry I. Jacobson et al.

Filing Date : October 9, 2003

Title: : CARDIOELECTROMAGNETIC TREATMENT

Examiner : Unassigned


Group Art Unit : 3762

Type of Document(s) : Express Mail Certificate;  
Transmittal Form (PTO/SB/21);  
Information Disclosure Statement (in dup.);  
PTO/SB/08a  
56 References (5 foreign patent documents and 51  
articles); and  
Return Postcard

I hereby certify that the documents identified above are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated below and are addressed to Commissioner for Patents, Mail Stop Amendment, P.O. Box 1450, Alexandria, VA 22313-1450.

Kay Farmer (signature)  
Kay Farmer

Date Mailed: August 27, 2004



Express Mail EV 367 776 298 US

PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM***(to be used for all correspondence after initial filing)*

<b>Application Number</b>	10/682,131		
	<b>Filing Date</b>	October 9, 2003	
	<b>First Named Inventor</b>	Jerry I. Jacobson	
	<b>Art Unit</b>	3762	
	<b>Examiner Name</b>	Not yet assigned	
<b>Total Number of Pages in This Submission</b>	65	<b>Attorney Docket Number</b>	35733/293661

**ENCLOSURES (check all that apply)**

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below): <b>Express Mail Certificate EV 367 776 298 US; PTO/SB/08a; 56 References; Return postcard</b>
<b>Remarks</b>		

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

<b>Firm or Individual name</b>	Cynthia B. Rothschild, Reg. No. 47,040, Kilpatrick Stockton LLP
<b>Signature</b>	
<b>Date</b>	August 27, 2004

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

<b>Typed or printed name</b>	Sent via express mail		
<b>Signature</b>		<b>Date</b>	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



EV 367 776 298 US  
PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of : Jerry I. Jacobson  
Serial No. : 10/682,131  
Filing Date : October 9, 2003  
Title : Cardioelectromagnetic Treatment  
Examiner : Not yet assigned  
Group Art Unit : 3762

Mail Stop Amendment  
Assistant Commissioner of Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98, Applicant submits herewith on Form PTO/SB/08A a listing of eighty-two (82) documents known to the Applicant and/or his attorney. Applicant respectfully requests consideration of the cited documents and making the same of record in the prosecution of the above-identified application. In so doing, Applicant does not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the present application, or to establish that such references are not prior art. Pursuant to the Notice in the Official Gazette of August 5, 2003, wherein the Patent Office waived the requirements of 37 C.F.R. § 1.98(a)(2)(i), Applicant has not enclosed copies of the U.S. patent references. Copies of the five (5) foreign patent documents and fifty-one (51) non-patent literature documents are enclosed, numbered and labeled for identification purposes.

This statement should not be construed as a representation that more material information does not exist or that a search of the relevant art has been made. It is respectfully requested that the references listed on the attached form PTO/SB/08a be expressly considered by the Examiner, made of record in the application, and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being submitted prior to the mailing of a first action on the merits in the present application. Accordingly, it is believed that no fees are due for consideration of this Information Disclosure Statement. However, should any fees be due, the Assistant Commissioner is authorized to charge such fees to Deposit Account 16-1435. A duplicate of this sheet is attached for that purpose.

Date: August 27, 2004

**KILPATRICK STOCKTON LLP**  
1001 West Fourth Street  
Winston-Salem, North Carolina 27101-2400  
(336) 747-7541 Phone  
(336) 607-7500 Facsimile  
**Attorney Docket No.: 35733/293661**

Respectfully submitted,

  
\_\_\_\_\_  
Cynthia B. Rothschild, Reg. No. 47,040

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

6

**Complete if Known**

Application Number	10/682,131
Filing Date	October 9, 2003
First Named Inventor	JACOBSON, Jerry I. et al.
Art Unit	3762
Examiner Name	Not Yet Assigned
Attorney Docket Number	35733-293661

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
	1	US-781,448	01-31-1905	McIntyre	
	2	US- 2,099,511	11-16-1937	Caesar	
	3	US- 2,103,440	12-28-1937	Weissenberg	
	4	US- 3,738,369	06-12-1973	Adams et al.	
	5	US- 3,890,953	06-24-1975	Kraus et al.	
	6	US- 3,967,215	06-29-1976	Bellak	
	7	US- 4,047,068	09-06-1977	Ress et al.	
	8	US- 4,323,056	04-06-1982	Borrelli et al.	
	9	US- 4,524,079	06-18-1985	Hofmann	
	10	US- 4,576,172	03-18-1986	Bentall	
	11	US- 4,611,599	09-16-1986	Bentall et al.	
	12	US- 4,674,481	06-23-1987	Boddie et al.	
	13	US- 5,019,076	05-28-1991	Yamanashi	
	14	US- 5,198,181	03-30-1993	Jacobson	
	15	US- 5,269,746	12-14-1993	Jacobson	
	16	US- 5,366,435	11-22-1994	Jacobson	
	17	US- 5,964,759	10-12-1999	Yamanashi	
	18	US- 6,004,257	12-21-1999	Jacobson	
	19	US- 6,022,479	02-08-2000	Smirnov	
	20	US- 6,059,781	05-09-2000	Yamanashi	
	21	US- 6,099,459	08-08-2000	Jacobson	
	22	US- 6,280,376	08-28-2001	Holcomb	
	23	US- 6,287,614 B1	09-11-2001	Peiffer	
	24	US- 6,458,071 B1	10-01-2002	Jacobson	
	25	US- 6,579,375 B2	05-08-2003	Beckett et al.	
	26	US- 6,733,434 B2	02-06-2003	Jacobson	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	27	WO 9531939	11-30-1995	Jacobson		
	28	WO 0013749	03-16-2000	Jacobson		
	29	WO 0115775	03-08-2001	Jacobson		
	30	EP 37 1 504	06-06-1990	Jacobson		
	31	AU-B-45680189	06-07-1990	Jacobson		

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 6

**Complete if Known**

Application Number	10/682,131
Filing Date	October 9, 2003
First Named Inventor	JACOBSON, Jerry I. et al.
Art Unit	3762
Examiner Name	Not Yet Assigned
Attorney Docket Number	35733-293661

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	32	ADEY, W. R., "Physiological Signalling Across Cell Membranes and Cooperative Influences of Extremely Low Frequency Electromagnetic Fields", Springer - Verlag, Biological Coherence and Response to External Stimuli, Herbert Frohlich (Ed.), 1998, pgs. 148-170	
	33	ADEY, W. R., "Tissue Interactions With Nonionizing Electromagnetic Fields", Physiological Reviews, Vol. 61, No. 2, April 1981, pgs. 435-514	
	34	ANNINOS, P. A. et al., "The Biological Effects of Magnetic Stimulation in Epileptic Patients," Panminerva Medica, Vol. 41, No. 3, 1999, pgs. 207-215	
	35	ANNINOS, P. A. et al., "Magnetic Stimulation in the Treatment of Partial Seizures," Intern. J. Neuroscience, Vol. 60, 1991, pgs. 141-175	
	36	BEALL, P. T. et al., "Distinction of Normal, Preneoplastic, and Neoplastic Mouse Mammary Primary Cell Cultures by Water Nuclear Magnetic Resonance Relaxation Times," JNCI., Vol. 64, No. 2, February 1980, pgs. 335-338	
	37	BISTOLFI, F., "Biostructures and Radiation Order Disorder," Edizioni Minerva Medica, Corso Bramante 83/85 - Torino, 1991, pgs. 61-92 and 261	
	38	CHENG, David K., Field and Wave Electromagnetics, Addison Wesley Publishing Company, 1983, pgs. 225-251, 569-576	
	39	CLEGG, J. S., "Intracellular Water and the Cytomatrix: Some Methods of Study and Current Views," The Journal of Cell Biology, Vol. 99, No. 1, 1984, pgs. 167s-171s	
	40	CLEGG, J. S., "Intracellular Water, Metabolism and Cell Architecture; Part 2," Coherent Excitations in Biological Systems, Springer - Verlag Berlin Heidelberg, H. Frohlich et al. (Eds.), 1983, 162-177	
	41	CLEGG, J. S., "Properties and Metabolism of the Aqueous Cytoplasm and Its Boundaries," The American Physiological Society, 1984, pgs. R133-R151	
	42	COHEON, D., "Magnetoencephalography: Detection of the Brain's Electrical Activity with a Superconducting Magnetometer, Science, Vol. 175, September 23, 1971 pgs. 664-666	
	43	CREMER-BARTELS, G., "Influence of Low Magnetic-Field-Strength Variations on the Retina and Pineal Gland of Quail and Humans," Graefe's Archive Ophthalmology, Vol. 220, 1983, pgs. 248-252	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 3 of 6

**Complete if Known**

Application Number	10/682,131
Filing Date	October 9, 2003
First Named Inventor	JACOBSON, Jerry I. et al.
Art Unit	3762
Examiner Name	Not Yet Assigned
Attorney Docket Number	35733-293661

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	44	EGAN, T. F. et al., "Molecular Basis of Contrast in MRI," Cell Function and Disease, Plenum Press, New York and London, Cañedo et al. (Eds.), 1988, pgs. 405-413	
	45	EICHHORN, G. L., "Aging, Genetics and the Environment: Potential of Errors Introduced Into Genetic Information Transfer by Metal Ions," Mechanisms of Ageing and Developments Vol. 9, 1979, pgs 291-301	
	46	HAZLEWOOD, C. F., "Implications of Cellular Water in Health and Disease," Second Annual Advanced Water Sciences Symposium, Dallas TX, October 4-6, 1996, pgs. 1-5	
	47	HAZLEWOOD, C. F., "A Role for Water in the Exclusion of Cellular Sodium - Is a Sodium Pump Needed?" Cardiovascular Diseases, Bulletin of the Texas Heart Institute, Vol. 2, no. 1, 1975, pgs 83-104	
	48	HAZLEWOOD, C. F., "A View of the Significance and Understanding of the Physical Properties of Cell-Associated Water," Cell-Associated Water, Academic Press, Inc., 1979, pgs. 165-259	
	49	HAZLEWOOD, C. F., "Diffusion of Water in Tissues and MRI," Magnetic Resonance in Medicine, Vol. 19, 1991, pgs. 214-216	
	50	JACOBSON, J. I., "Jacobson Resonance: The Coupling Mechanism for Weak Electromagnetic Field Bioeffects, and a New Way to Approach Magneto Therapy," Panminerva Medica, Vol. 36, No. 1, March 1994, pgs. 34-41	
	51	JACOBSON, J. I., "Exploring the Potential of Magneto-Recrystallization of Genes and Associated Structures With Respect to Nerve Regeneration and Cancer," Int. Journal of Neuroscience, Vol. 64, No. 1-4, 1992, pgs. 153-165	
	52	JACOBSON, J. I., "Is the Fusion Process the Basis for Growth, Repair and Aging?" Panminerva Medica, Vol. 32, No. 3, July - September 1990, pgs. 132-140	
	53	JACOBSON, J. I., et al., "Pico Tesla Range Magnetic Fields Tested in Four Site, Double Blind Clinical Study for Treatment of Osteoarthritic Knees," Gazzetta Medica Italiana - Arch. Sci. Med., Vol. 160, 2001, pgs. 1-21	
	54	JACOBSON, J. I., "Jacobson Resonance: The Quantum-mechanical Basis for a Novel Radiological Approach to Treating Cancer and Aids," Frontier Perspectives, Vol. 6, No. 1, Fall/Winter 1996, pgs. 17-26	
	55	JACOBSON, J. I., "Jacobson Resonance is the Basis From Which to Evaluate Potential Hazard and Therapeutic Benefit From Extrinsic Magnetic Fields," Panminerva Medica, Vol. 35, No. 3, September 1993, pgs. 138-148	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 4 of 6

**Complete if Known**

Application Number	10/682,131
Filing Date	October 9, 2003
First Named Inventor	JACOBSON, Jerry I. et al.
Art Unit	3762
Examiner Name	Not Yet Assigned
Attorney Docket Number	35733-293661

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	56	JACOBSON, J. I., "A Look at the Possible Mechanism and Potential of Magneto Therapy," Journal of Theoretical Biology, Vol. 149, No. 1, March 7, 1991, pgs. 97-119	
	57	JACOBSON, J. I., "Physics in Medicine: A Potential Unfolding in the Radiological Sciences," Panminerva Medica, Vol. 39, No. 2, February 13, 1996, pgs. 111-127	
	58	JACOBSON, J. I., "Pineal-Hypothalamic Tract Mediation of Picotesla Magnetic Fields in the Treatment of Neurological Disorders," Panminerva Medica, Vol. 36, No. 4, December 1994, pgs. 201-205	
	59	JACOBSON, J. I., "The Question of Ameliorating the Aging Process, Even Macula Regeneration With Magnetic Fields," Panminerva Medica, Vol. 33, No. 4, 1991, pgs. 205-208	
	60	JACOBSON, J. I., "A Theoretical Look at Gravity in the Human Cell: Its Role in Normal Cell Division as Well as Neoplasia," Panminerva Medica, Vol. 34, No. 3, 1992, pgs. 99-106	
	61	JACOBSON, J. I. et al., "A Possible, Physical Mechanism in the Treatment of Neurologic Disorders with Externally Applied Pico Tesla Magnetic Fields," Physiol. Chem. Phys. & Med. NMR, Vol. 26, 1994, pgs. 287-297	
	62	KASTURI, S. R., "Study of Anisotropy Nuclear Magnetic Resonance Relaxation Times of Water Protons in Skeletal Muscle," Biophys. J., Vol. 30, June 1980, pgs 369-381	
	63	KASTURI, S. R., "The Nature and Origin of Chemical Shift for Intracellular Water Nuclei in Artemia Cysts," Biophys. J., Vol. 52, August 1987, pgs. 249-256	
	64	KASTURI, S. R., "Intracellular Water in Artemia Cysts (Brine Shrimp) Investigations by Deuterium and Oxygen-17 Nuclear Magnetic Resonance," Biophys. J., Vol. 58, August 1990, pgs. 483-491	
	65	LAWRENCE, A. F., et al., "Nonlinear Wave Mechanisms in Interactions between Excitable Tissue and Electromagnetic Fields," Neurological Research, Vol. 4, No. 1/2, 1982, pgs. 115-153	
	66	MIKESELL, Norman deLauder, "Structured Water: Its Healing Effects on the Diseased State," web-page at <a href="http://www.naturesalternatives.com/lc/mikesell.html">http://www.naturesalternatives.com/lc/mikesell.html</a> as created on the internet February 27, 1999	
	67	REUSS, S., "Different Types of Magnetically Sensitive Cells in the Rat Pineal Gland," Neuroscience Letters, Vol. 40, 1983, pgs. 23-26	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 5 of 6

**Complete if Known**

Application Number	10/682,131
Filing Date	October 9, 2003
First Named Inventor	JACOBSON, Jerry I. et al.
Art Unit	3762
Examiner Name	Not Yet Assigned
Attorney Docket Number	35733-293661

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	68	RORSCHACH, H. E. et al., "Diffusion of Water in Biological Tissues," Scanning Microscopy Supplement 5, 1991, pgs. S1-S9	
	69	SANDYK, R., "Alzheimer's Disease: Improvement of Visual Memory and Visuoconstructive Performance by Treatment with PicoTesla Range Magnetic Fields," Intern. J. Neuroscience, Vol. 76, 1994, pgs. 185-225	
	70	SANDYK, R., "Clinical Case Report Magnetic Fields in the Treatment of Parkinson's Disease," Intern. J. Neuroscience, Vol. 63, 1992, pgs. 141-150	
	71	SANDYK, R., "Clinical Case Report Successful Treatment of Multiple Sclerosis With Magnetic Fields," Intern. J. Neuroscience, Vol. 66, 1992, pgs. 237-250	
	72	SAXENA, A., et al., "A Hypothetical Mathematical Construct Explaining the Mechanism of Biological Amplification in an Experimental Model Utilizing PicoTesla (PT) Electromagnetic Fields," Medical Hypotheses Vol. 60, No. 6, 2003, pgs. 821-839	
	73	SCHERLAG, Benjamin J. et al, "The Application of Low-Level Electromagnetic Fields to the Autonomic Nerve Inputs to the Heart: Effects on Heart Rate and Atrioventricular Conduction," abstract presented at annual meeting of the American Institute of Stress, in Hawaii, 2000	
	74	SCHERLAG, Benjamin J. et al, "Magnetism and Cardiac Arrhythmias," Cardiology in Review, Vol. 12, No. 2, March/April 2004, pgs. 85-96	
	75	SCHERLAG, Benjamin J. et al, "Use of Low-Level Electromagnetic Fields and Vago-Sympathetic Stimulation to Detect and Induce the Paroxysmal Atrial Fibrillation Syndrome," abstract presented at annual meeting of the American Institute of Stress, in Hawaii, 2000	
	76	SEITZ, P. K., "Proton Magnetic Resonance Studies on the Physical State of Water in Artemia Cysts," The Brine Shrimp Artemia, Vol. 2, 1980, pgs. 545-554	
	77	TROSTEL, C. T., DVM, et al., "Effects of Pico-Tesla Electromagnetic Field Treatment on Wound Healing in Rats," Am. J. Veterinary Res., Vol. 64, No. 7, July 2003, pgs. 845-854	
	78	WANGSNESS, Roald K., Electromagnetic Fields, John Wiley & Sons, Chapter 14, 1986, pgs. 225-236	
	79	WELKER, H. A., "Effects of an Artificial Magnetic Field on Serotonin N-Acetyltransferase Activity and Melatonin Content of the Rat Pineal Gland," Exp. Brain Res., Vol. 50, 1983, pgs. 426-432	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 6 of 6

**Complete if Known**

Application Number	10/682,131
Filing Date	October 9, 2003
First Named Inventor	JACOBSON, Jerry I. et al.
Art Unit	3762
Examiner Name	Not Yet Assigned
Attorney Docket Number	35733-293661

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	80	YAMANASHI, W. et al. "The Effect of Low-Level Electromagnetic Fields on a Simple Model of Osmosis, in Vitro, abstract presented at annual meeting of the American Institute of Stress, in Hawaii, 2000	
	81	"Oklahoma University researchers report dramatic growth effects of bean sprouts using Jacobson resonance," presented to the Indian Medical Association, Calcutta, India, 2002	
	82	"Jacobson Resonance Enterprises, Inc. Announces Research Findings in Breast Cancer Cells from the College of Veterinary Medicine at Mississippi State University," press release April 30, 2004	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.